Holen Sie sich die Stockscreener-App
0.3736
7.48%
-0.0302
Handel nachbörslich:
.37
-0.0036
-0.96%
Senti Biosciences Holdings Inc Aktie (SNTI) Neueste Nachrichten
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SNTI|Senti Biosciences Inc|Price:0.448| - TradingKey
$Senti Biosciences (SNTI.US)$ - Moomoo
Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Senti Biosciences (SNTI) outlines CVR-only merger, reverse split and note share issuance - Stock Titan
Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com - Investing.com South Africa
Senti Biosciences (SNTI) backer plans merger and $6M funding - Stock Titan
Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform - Quiver Quantitative
Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs - TradingView
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Te - Yahoo Finance
Senti Bio Stockholders Could Receive Up to $60M From SENTI-202 - Stock Titan
SNTI Should I Buy - Intellectia AI
Price to sales forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Price to book forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBITDA forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI) - TradingView
SNTI Forecast — Price Target — Prediction for 2027 - TradingView
Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes - Stock Titan
Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SNTI Q1 2026 Earnings: Modest EPS Beat Amid Development ProgressEarnings Call Transcript - dars.gov.et
Senti Biosciences Inc (SNTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction - Business Wire
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
SNTISenti Biosciences Holdings Inc Options - Finviz
Senti Biosciences Inc. (SNTI) Stays Near Key Support Following Modest UptickTake Profit Levels - The Legal Advocate
Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR - Stock Titan
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch - Bez Kabli
Senti Biosciences Inc. Q1 2026 Earnings: Narrowing Losses and Gene Circuitry ProgressCFO Commentary Report - Newser
Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy - The Clinical Trial Vanguard
Senti Biosciences Holdings, Inc.Common Stock (NQ: SNTI - The Chronicle-Journal
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - TipRanks
SNTI Maintained by Chardan Capital -- Price Target Raised to $12 - GuruFocus
Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating - Moomoo
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Sahm
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
Senti Biosciences Advances SENTI-202 to Pivotal Phase for AML, Secures $40M Financing, and Reports Reduced Q1 2026 Loss - Minichart
Senti Biosciences 1Q Loss $4.22M >SNTI - Moomoo
Senti Biosciences Advances SENTI-202 With New FDA Support - TipRanks
Senti Bio plans pivotal trial for AML therapy after FDA meeting - Investing.com
Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy - marketscreener.com
Senti Bio plans pivotal trial for AML therapy after FDA meeting By Investing.com - Investing.com South Africa
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy - TradingView
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding - Stock Titan
Senti Biosciences 1Q Loss/Shr 14c >SNTI - Moomoo
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase - Yahoo Finance
SNTI Q1'26 Earnings: EPS estimate is (0.36) USD - TradingView
Number of shareholders of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
[15-12G] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences Holdings, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SNTI | US8169441024 - marketscreener.com
Why Senti Biosciences (SNTI) looks attractive at current levels (Breakout Watch) 2026-05-06RSI Overbought Stocks - newser.com
Celadon backs Senti Biosciences (SNTI) with $40M notes and majority stake - Stock Titan
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):